Medically reviewed by Christopher Koller, M.D., director of urologic oncology at Hackensack Meridian Clifton Health and Wellness Center at Clifton Prostate cancer is the most common cancer in men across the United States — and it’s on the rise, particularly in New…
Record US Quarter: How Is Cyclopharm (ASX:CYC) Building on It? New Leaders, Big Test: Where Is IPH (ASX:IPH) Heading at Its AGM? The milestone is significant for a clinical-stage company whose valuation rests heavily on the success of…
Dr. Nastiuk initiated the current study to better understand how hormonal anti-androgen therapy (ADT) reshapes the immune landscape around prostate cancers. What is already known on this topic What this study adds This investigation was supported by the National Cancer…
- Aamir Malik, Executive Vice President, Chief U.S. Commercial Officer, Pfizer - Neeraj Agarwal, M.D., FASCO, Co-director of Prostate Cancer Program at Harvard Cancer Consortium, faculty medical oncologist at Dana-Farber Cancer Institute, and global lead investigator for TALAPRO-3 TALZENNA plus XTANDI was first approved…
Wollongong-based online news outlet covering Australia and beyond. If you have anything newsworthy - a story, video or picture to share with us, please email us. Individuals' genetic background may affect ceramide metabolism to influence whether they benefit from androgen receptor…
Newswise — In a recent Yale-led clinical trial, a new type of prostate cancer drug showed promising results in reducing tumor activity and pain for patients with metastatic prostate cancer. “This is a first-in-class drug for prostate cancer,” says Daniel Petrylak,…
Wollongong-based online news outlet covering Australia and beyond. If you have anything newsworthy - a story, video or picture to share with us, please email us. By Dr Wendy Winnall - PCFA Research Team Biopsy of the prostate remains the standard method…
Planned physician education and a future software release are intended to connect PSMA-PET data with MRI-guided treatment planning. Profound is also developing PSMA-PET/MR image-fusion capabilities for a planned future release of its Treatment Delivery Console software. The planned functionality…
Researchers at Fred Hutch Cancer Center have identified a previously overlooked molecular regulator that helps determine whether prostate tumors remain sensitive to treatment or evolve into a more aggressive, drug-resistant form of the disease. The findings, published Oct. 7 in Nature,…
READ MORE PREVIOUS ARTICLES A. Oliver Sartor, MD, Director of the Transformational Prostate Cancer Research Center at Tulane University School of Medicine. He is a recognized leader in prostate cancer research and radioligand therapy, with expertise spanning clinical investigation, treatment development,…
Prostate, testicular, CV screening, skin checks, and healthy aging basics.
An article joins this feed when it matches these terms. Each one is also a search of its own.